Wegovy Subscription Saves NVO Shares from Five-Year Lows
Shares of Novo Nordisk (NVO) experienced a continued descent on Monday, reaching their lowest point in five years. This movement comes amidst significant devel…
Shares of Novo Nordisk (NVO) experienced a continued descent on Monday, reaching their lowest point in five years. This movement comes amidst significant developments from rival pharmaceutical company Eli Lilly (LLY), which appear to be overshadowing the Danish GLP-1 drug manufacturer. Separately, Novo Nordisk announced on Tuesday the introduction of a new multi-month subscription offering for its weight-loss medication, Wegovy.
Novo Nordisk (NVO) currently holds an RS Score of 65.70, placing it in the 36.64th percentile within both its country and sector. The stock demonstrates strength in Valuation (96.40), Growth (95.54), and Profitability (96.05). Conversely, areas like Momentum (11.59) and EPS Revisions (64.00) appear comparatively weaker. Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.